Clinical Study On Banxia Xiexin Decoction In Prevention And Treating Of Irinotecan Induced Delayed Diarrhea

Objective: To study and analyze the effectiveness and safety of Banxia Xiexin Decoction in the prevention and treatment of delayed diarrhea caused by irinotecan chemotherapy,in order to guide the clinical diagnosis and treatment of cancer chemotherapy side effects.Methods: A randomized control method was used to collect 62 patients with colorectal cancer and small cell lung cancer who met the inclusion criteria from2020.05-2020.12 in the Department of Oncology,Hospital of Chengdu University of Traditional Chinese Medicine,and randomly divided them into a treatment group and a control group with 31 cases each.The treatment group was given FOLFIRI,XELIRI,IP or IC chemotherapy regimen,and Banxia Xiexin Decoction was given from the day before until the end of the first cycle of chemotherapy(14 days).The control group was given chemotherapy and placebo.Observe the patients with delayed diarrhea after chemotherapy,the frequency,traits and other related symptoms,etc.,and the data of colorectal cancer and small cell lung cancer were extracted from the overall samples of each group as subgroups for comparison.Result: 1.Comparison of the incidence of CID and the grade of diarrhea: After chi-square test and non-parametric rank sum test,chi-square test and non-parametric rank sum test,the overall and small cell lung cancer subgroups had statistical significance in the incidence of diarrhea(P<0.05),and the colorectal cancer subgroup had diarrhea The incidence rate was not statistically significant(P>0.05).Overall,colorectal cancer subgroups,small cell lung cancer subgroups were statistically significant in the grade of delayed diarrhea(P<0.05).2.Comparison of the time and duration of first occurrence of CID: After independent sample t-test analysis,the difference between the overall and colorectal cancer group’s initial occurrence time was statistically significant(P<0.05),and the difference between small cell lung cancer subgroups was not statistically significant(P>0.05).All results were statistically significant in the duration of diarrhea between the two groups(P<0.05).3.Comparison of Bristol stool characteristics: According to the chi-square test,on the second,seventh,and 14 th days after chemotherapy,there was no statistically significant difference in the incidence of Bristol stool traits between the two groups of patients with type 6 and type 7(P>0.05).4.CID average times comparison: According to the t-test analysis of two independent samples,the overall time node on day 2 and 7 after chemotherapy,the colorectal cancer subgroup on day 7 after chemotherapy,the treatment group and the control group on the second day of small cell lung cancer subgroup The comparison between the groups was statistically significant(P<0.05),and there was no significant difference between the other time nodes and groups(P>0.05).5.KPS score comparison: After the non-parametric rank sum test,the increase of KPS score in the treatment group of Banxia Xiexin Decoction was higher than that of the control group after the treatment cycle,and the difference between the two groups was statistically significant(P<0.05).6.Safety comparison: After the non-parametric test and the Chi-square test,the Banxia Xiexin Decoction treatment group has bone marrow suppression(WBC,Hb,NEU,PLT),liver damage(ALT),renal damage(BUN,Scr),There was no significant difference in the incidence of side effects such as nausea and vomiting,loss of appetite,abdominal distension and abdominal pain between the two groups(P>0.05).Conclusion: Banxia Xiexin Decoction can prevent and treat late-onset diarrhea caused by irinotecan in the irinotecan-containing chemotherapy regimens(IP,IC,FOLFIRI,XELIRI)for small cell lung cancer and colorectal cancer,and can significantly improve the KPS physical status score of patients,and have good safety.